SCHEMBL7299170

SCHEMBL7299170

CC(C)=CCCC(C)=CCCO

nearest known ligand 0.78

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SQLE Q14534 7/20 0.78
KMT2A Q03164 3/20 0.76
MAPT P10636 2/20 0.74
MEN1 O00255 2/20 0.74
CYP3A4 P08684 2/20 0.74
ALOX15 P16050 2/20 0.74
ALDH1A1 P00352 1/20 0.74
UGT1A1 P22309 1/20 0.74
ICMT O60725 1/20 0.62
KDM4E B2RXH2 1/20 0.59
FNTA P49354 1/20 0.53
FNTB P49356 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5595473 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL18037035 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL8512384 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL9738963 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL17312900 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL2636615 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL19228659 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL1105229 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL5595479 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL586128 1.00 SQLE (0.78) SQLEKMT2AMAPTMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119876059-A Biological catalytic synthesis method of ambrox 天津大学浙江研究院(绍兴) 2025-04-25 CN disclosed
WO-2023018326-A1 SYNTHESIS OF ALKYL TRIAZOLE GLYCOSIDE (ATG) FOR OIL IN WATER APPLICATION PETROLIAM NASIONAL BERHAD (PETRONAS) (MY) 2023-02-16 WO disclosed
EP-2948245-B1 PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES FIRMENICH & CIE (CH) 2018-05-30 EP disclosed
US-9381507-B2 Process for the preparation of 4-methylpent-3-en-1-ol derivatives FIRMENICH SA (CH) 2016-07-05 US disclosed
US-20150353463-A1 PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES FIRMENICH SA (CH) 2015-12-10 US disclosed
EP-2948245-A1 PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES Firmenich SA (CH) 2015-12-02 EP disclosed
WO-2014114615-A1 PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES FIRMENICH SA (CH) 2014-07-31 WO disclosed
US-5155239-A Preparation of polycyclic ethers FIRMENICH S.A. (CH) 1992-10-13 US disclosed
US-5155238-A Acidic cyclization of polyunsaturated, acyclic alcohol or protected alcohol; stereospecific; organoleptic FIRMENICH S.A. (CH) 1992-10-13 US disclosed
US-5077417-A Acidifying, cyclizing a polyunsaturated alicyclic alcohol or protected hydroxy group FIRMENICH SA (CH) 1991-12-31 US disclosed
EP-0403945-A2 Cycloaliphatic carbinols and their use as starting materials for the preparation of furan derivatives FIRMENICH SA (CH) 1990-12-27 EP disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
US-4137273-A INSECTICIDES, CHEMICAL INTERMEDIATES ZOECON CORPORATION (US) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353463-A1 PROCESS FOR THE PREPARATION OF 4-METHYLPENT-3-EN-1-OL DERIVATIVES CYP4A11, CYP4B1, CYP51A1 SQLE 53/4885KMT2A 391/4885MAPT 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.